Cargando…

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine

Detalles Bibliográficos
Autores principales:	Kazmi, Shayma, Chatterjee, Debanjana, Raju, Dheeraj, Hauser, Rob, Kaufman, Peter A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496657/ https://www.ncbi.nlm.nih.gov/pubmed/33907908 http://dx.doi.org/10.1007/s10549-021-06223-6

Ejemplares similares

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2020)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
por: Lin, Yu-Ju, et al.
Publicado: (2021)

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
por: Cortes, Javier, et al.
Publicado: (2015)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
por: López-Álvarez, María, et al.
Publicado: (2022)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Bianconi, Daniela, et al.
Publicado: (2017)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
por: Kaufman, Peter A., et al.
Publicado: (2015)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
por: Twelves, Chris, et al.
Publicado: (2016)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
por: Mougalian, Sarah S., et al.
Publicado: (2021)

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
por: Waters, J S, et al.
Publicado: (2004)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
por: Miyoshi, Yasuo, et al.
Publicado: (2020)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
por: Yamamoto, Akinaru, et al.
Publicado: (2020)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
por: Twelves, Chris, et al.
Publicado: (2019)

Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
por: Vernieri, Claudio, et al.
Publicado: (2020)

Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma
por: Liao, Wenjun, et al.
Publicado: (2021)

Correction: Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial
Publicado: (2019)

Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
por: Chen, Pei-Hsin, et al.
Publicado: (2021)

Regression of brain metastases from breast cancer with eribulin: a case report
por: Matsuoka, Hiromichi, et al.
Publicado: (2013)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2015)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lvcm57p8iurjbs2pokul8ml44c